Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Outcomes of patients with triple-class refractory myeloma: a single-center retrospective study

James Berenson • 11 Dec 2023
ASH 2023
Multiple Myeloma Antibodies Bortezomib Carfilzomib Daratumumab Lenalidomide Pomalidomide

James Berenson, MD, Berenson Cancer Center, West Hollywood, CA, shares insights into a single-center retrospective study evaluating the outcomes of patients with triple-class refractory multiple myeloma, highlighting the promise of novel agents and combinations in this patient population. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research Funding: Incyte Corporation

More from James Berenson

1:16
The addition of isatuximab to KRd improves transplant outcomes for patients with multiple myeloma
James Berenson • 14 Dec 2023
1:09
Medical writing bias in myeloma clinical research
James Berenson • 11 Dec 2023
2:07
Addition of lenalidomide to patients with myeloma progressing on ruxolitinib and methylprednisolone
James Berenson • 11 Dec 2023
1:04
Mechanism of action of belantamab mafodotin
James Berenson • 12 Oct 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals